Pharmacokinetic studies overview

In an overview on CE for pharmaceutical applications, Altria describes the analysis of ionic salts, organic acids, and also water purity, which may have deleterious effects on synthetic processes. In her review, Natishan " also included indirect UV detection when performing pharmacokinetic studies. 

Witkiewicz et al have comprehensively reviewed the application of chromatographic methods to the analysis of chemical warfare agents. A brief overview is presented below with the emphasis on applications in verification analysis and pharmacokinetic studies. 

PS Bunerjee. JR Robinson. Novel drug delivery systems. An overview of their impact on clinical and pharmacokinetic studies. Clin. Pharmacokin 20 1-14. 1991. 

This chapter will review some of the important methods for carrying out in vivo absorption and bioavailability studies, as well as attempt to provide an overview of how the information may be used in the drug discovery process. The chapter is aimed at medicinal chemists and thus will focus on the use of animals in discovery phase absorption, distribution, metabolism, and excretion/pharmacokinetic (ADME/PK) studies, rather than the design of studies that are for regulatory submission, or part of a development safety package. 

Many drugs have been recognized to cross the intestinal epithelial cells via passive diffusion, thus their lipophilicity has been considered important. However, as described above, recent studies have demonstrated that a number of drug transporters including uptake and efflux systems determine the membrane transport process. In this chapter, we provide an overview of the basic characteristics of major drug transporters responsible not only for absorption but also for disposition and excretion in order to delineate the impact of drug transport proteins on pharmacokinetics. 

Having access to metabolism data in the early discovery stage is invaluable. For example, hepatic metabolism data could be used to characterize the pharmacokinetic behavior of a perspective lead. Several studies have reported how metabolism databases and software systems have been used at various settings (272). In this section, we will provide an overview of recent databases, software systems, websites, tools, and services that could be potential starting points for metabolism modeling at various stages in drug discovery process (271,273). 

In fact, physiologically based pharmacokinetic models are similar to environmental fate models. In both cases we divide a complicated system into simpler compartments, estimate the rate of transfer between the compartments, and estimate the rate of transformation within each compartment. The obvious difference is that environmental systems are inherently much more complex because they have more routes of entry, more compartments, more variables (each with a greater range of values), and a lack of control over these variables for systematic study. The discussion that follows is a general overview of the transport and transformation of toxicants in the environment in the context of developing qualitative and quantitative models of these processes. 

Md.K. Pasha, S. Muzeeb, S.J.S. Basha, D. Shashikumar, R. Mullangi, N.R. Srinivas, Analysis of five HMG-CoA reductase inhibitors—atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies, Biomed. Chromatogr. 20 (2006) 282-293. 

Pharmacokinetics in animals depend on the species studied as well as the route of administration. liable 3 gives a brief overview. 

A comparative study of the pharmacokinetic and pharmacodynamic properties of the more modern fluoroquinolones [218,219], as well as overviews on the pharmacokinetics [163,220] and pharmacodynamics [221] of moxifloxacin, can be found in the literature. 

To illustrate the amount of data that can be obtained using the study type under discussion, an overview of the pharmacokinetic and the deconvolution results obtained from the study described above under Procedure is presented below. 

Recent advances in mass spectrometry have rendered it an attractive and versatile tool in industrial and academic research laboratories. As a part of this rapid growth, a considerable body of hterature has been devoted to the apph-cation of mass spectrometry in clinical studies. In concert with separation techniques such as hquid chromatography, mass spectrometry allows the rapid characterization and quantitative determination of a large array of molecules in complex mixtures. Herein, we present an overview of the above techniques accompanied with several examples of the use of liquid chromatography-tandem mass spectrometry in pharmacokinetics/drug metabohsm assessment during drug development. 

A number of excellent review articles exist, including several that explain MR spectroscopy and detail the impact of MR spectroscopy in drug design and in preclinical studies, and others that provide overviews of human in vivo metabolism and pharmacokinetics measured by 19F MR in fluoropyrimidine compounds as well as in psychotropic compounds [1, 3-5, 7-10, 59, 60-63], In keeping with other facets of drug development, the number of 19F MR clinical investigations is much smaller than the number of animal model, specimen, cell line, or solution experiments. 

There is at least one major area of activity pertaining directly to the environment for which the reader will seek in vain. The complexity of environmental problems and the availability of personal computers have led to extensive studies on models of varying sophistication. A discussion and evaluation of these lie well beyond the competence of an old-fashioned experimentalist this gap is left for others to fill but attention is drawn to a review that covers recent developments in the application of models to the risk assessment of xenobiotics (Barnthouse 1992), a book (Mackay 1991) that is devoted to the problem of partition in terms of fugacity — a useful term taken over from classical thermodynamics — and a chapter in the book by Schwarzenbach et al. (1993). Some superficial comments are, however, presented in Section 3.5.5 in an attempt to provide an overview of the dissemination of xenobiotics in natural ecosystems. It should also be noted that pharmacokinetic models have a valuable place in assessing the dynamics of uptake and elimination of xenobiotics in biota, and a single example (Clark et al. 1987) is noted parenthetically in another context in Section 3.1.1. In similar vein, statistical procedures for assessing community effects are only superficially noted in Section 7.4. Examples of the application of cluster analysis to analyze bacterial populations of interest in the bioremediation of contaminated sites are given in Section 8.2.6.2. 

A series of reviews describing nicotine metabolism has recently appeared [2], Specific topics covered include the biosynthesis and metabolism of nicotine and related alkaloids [3], an overview of mammalian nicotine metabolism [4], the role of cytochrome P450 in nicotine metabolism [5], nicotine metabolism beyond cotinine [6], N-oxidation, A -methylation, and N-conjugation reactions of nicotine [7], extrahepatic metabolism of nicotine and related compounds [8], metabolism of the minor tobacco alkaloids [9], analysis and levels of nicotine and metabolites in body fluids [10], kinetics of nicotine and its metabolites in animals [11], pharmacokinetics of (S)-nicotine and metabolites in humans [12], and sources of inter-individual variation in nicotine pharmacokinetics [13]. Another recent review described variables which affect nicotine metabolism [14]. Several compilations of studies or reviews on the tobacco-specific A-nitrosamines are available [15-18]... 

The traditional pharmacokinetic (PK) study volunteer study in healthy children has proved very hard to set up, because of the attitude of many parents and overviewing independent review boards (IRBs). Even in pediatric patients, the frequency and total volume requirements for samples for conventional PK studies can cause the same refusals. However, there are pediatric research units that specialize in these studies, with minimum needle sticks, minute blood volumes, and IRBs sympathetic to the needs of the pediatric community. The National Institute of Child Health and Human Development has set up a network of pediatric pharmacology units , usually in academic regional centers, now numbering 13 units. There are other non-governmental specialized units also available for pediatric PK work. 

---